A medical assistant reported that a (b)(6) year old male received solesta (dextranomer/hyaluronic acid) injection into the submucosa of the anal canal as treatment for fecal incontinence.Additional medical history and concurrent medications were not provided.On (b)(6) 2015, the patient received solesta.Prophylactic antibiotics were not administered prior to implantation.On that same date, the patient experienced a fever and "not urinating as well".The patient was evaluated by his physician on (b)(6) 2014 and treatment began with acetaminophen/oxycodone and amoxicillin clavulanate.The patient was again seen by his physician on (b)(6) 2015 with complaints of rectal discomfort.On (b)(6) 2015, the patient was hospitalized for cellulitis in the rectal and urinary retention.While hospitalized, the patient received intravenous antibiotics and a foley catheter was inserted to treat the urinary retention.On (b)(6) 2015, the patient was discharged.The events were considered completely resolved on an unspecified date.The reporter felt the events were possibly related to the use of solesta.The company assessed the events as possibly related to solesta.
|